Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0GZGHN
ADC Name
SAR-566658
Synonyms
Anti-CA6-DM4-immunoconjugate-SAR566658; Anti-CA6-antibody-drug-conjugate; HuDS6-DM4; SAR 566658; SAR-566658; SAR56 6658; SAR566658; huDS6-DM4
   Click to Show/Hide
Organization
Sanofi; ImmunoGen, Inc.
Drug Status
Phase 2 (Terminated)
Indication
In total 2 Indication(s)
Breast cancer
Phase 2
Clinical Trial
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
1
Structure
Antibody Name
Anti-CA6 mAb huDS6
  Antibody Info 
Antigen Name
Carbonic anhydrase 6 (CA6)
  Antigen Info 
Payload Name
Mertansine DM4
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
  Linker Info 
Conjugate Type
Random Lysines
Combination Type
ravtansine
Puchem SID
160693199 , 472419458 , 381127620
DrugMap ID
DMT4FI5
TTD ID
D0G5YR
ChEBI ID
CHEMBL2109635
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT02984683
Phase 1
Open-label phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic triple negative breast cancer.
Undisclosed  NCT01156870
Phase 1
Dose escalation, safety and pharmacokinetic, first in man study, of SAR566658 administered as a single agent by intravenous infusion in adult patients with CA6-positive and refractory solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT02984683  Clinical Status Phase 1
Clinical Description Open-label phase 2 study evaluating efficacy and safety of SAR566658 treatment in patients with CA6 positive metastatic triple negative breast cancer.
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT01156870  Clinical Status Phase 1
Clinical Description Dose escalation, safety and pharmacokinetic, first in man study, of SAR566658 administered as a single agent by intravenous infusion in adult patients with CA6-positive and refractory solid tumors.
References
Ref 1 Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Ref 2 Dose Escalation, Safety and Pharmacokinetic, First in Man Study, of SAR566658 Administered as a Single Agent by Intravenous Infusion in Adult Patients With CA6-Positive and Refractory Solid Tumors